Gut microbiota modulation in gastrointestinal disorders: current evidence and therapeutic perspectives
Frontiers in Cellular and Infection Microbiology · 2026
DOI: 10.3389/fcimb.2025.1740322 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Meng-Ying Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intervention, Shanghai Xuhui Central Hospital, Shanghai, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Gastrointestinal Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gut microbiome medicine is a promising field in functional medicine, offering personalized treatment strategies for gastrointestinal disorders. Advanced metagenomic and metabolomic technologies have revealed the gut microbiome’s systemic influence, extending to distant organs like the brain and lungs. While small molecules and genes facilitate these effects, the gut microbiota’s greatest abundance and activity are concentrated in the gastrointestinal tract, particularly in the distal regions. The balance of microbial communities in the small and large intestines is crucial for gastrointestinal health. However, the dominance of pathogenic bacteria can disrupt this balance, leading to tissue damage and contributing to gastrointestinal disorders. Emerging interventions, such as probiotics, fecal microbiota transplantation, and dietary enrichment with short-chain fatty acids, show potential in restoring microbial balance, enhancing immune function, and potentially protecting against carcinogenesis. Current evidence from clinical trials and animal models supports the therapeutic role of gut microbiome modulation in reversing gastrointestinal disorders. However, variability in study outcomes highlights the need for further research to standardize these approaches for clinical practice. This review underscores the gut microbiome’s pivotal role in gastrointestinal health and the therapeutic promise of functional medicine in addressing these disorders. This review also explores emerging interventions, such as phage therapy and engineered microbes, and provides comparative analyses of microbiota signatures and therapeutic approaches across different gastrointestinal disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Intervention, Shanghai Xuhui Central Hospital, Shanghai, China.
- Department of Emergency Medical, Shanghai Baoshan District Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
- Department of Respiratory Medicine, Xiamen Traditional Chinese Medicine (TCM) Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Xiamen, Fujian, China.
- Department of Respiratory Medicine, Xiamen Hospital, Dongzhimen Hospital, Beijing University of Chinese Medicine, Xiamen, Fujian, China.
- Department of Gastroenterology, Heilongjiang Academy of Traditional Chinese Medicine, Harbin, China.
Zitieren
APA
Zhang, M. Y., Chen, S. Y., Lin, Y. H., & Yuan, X. X. (2026). Gut microbiota modulation in gastrointestinal disorders: current evidence and therapeutic perspectives. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1740322
Vancouver
Zhang MY, Chen SY, Lin YH, Yuan XX. Gut microbiota modulation in gastrointestinal disorders: current evidence and therapeutic perspectives. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2025.1740322
BibTeX
@article{Zhang2026,
author = {Zhang, Meng-Ying and Chen, Shao-Yu and Lin, Yu-Hua and Yuan, Xing-Xing},
title = {Gut microbiota modulation in gastrointestinal disorders: current evidence and therapeutic perspectives},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
doi = {10.3389/fcimb.2025.1740322}
}
EUVIMED